NLS Pharmaceutics AG

Aktienanalyse zu NLS Pharmaceutics AG (NLSP)

$7.620

+0.226 (+2.97%)Zum Schluss

Loading chart…
High
8.300
Open
7.701
VWAP
7.84
Vol
4.76M
Mkt Cap
10.41M
Low
7.600
Amount
37.34M
EV/EBITDA, TTM
0.00

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Bewertungskennzahlen

The current forward P/E ratio for NLS Pharmaceutics AG (NLSP) is -0.09, compared to its 5-year average forward P/E of -2.97.

Forward P/E

Overvalued
5Y Average P/E
-2.97
Current P/E
-0.09
Überbewertet
-0.47
Unterbewertet
-5.48

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward P/S

Fair
5Y Average P/S
46.79
Current P/S
0.00
Überbewertet
170.74
Unterbewertet
-77.16

Alphio AI Price Scenarios for NLSP

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NLSP

$2.96

Szenariopreis

B

Base

Base · 50%NLSP

$2.68

Szenariopreis

B

Bear

Bear · 25%NLSP

$2.50

Szenariopreis

Whales holding NLSP

B

BVF Partners L.P.

+ HoldingNLSP

+11.78%

3M Return

NLSP FAQ — answered by Alphio AI

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten